Recent Analysts’ Ratings Updates for Humacyte (HUMA)

Several brokerages have updated their recommendations and price targets on shares of Humacyte (NASDAQ: HUMA) in the last few weeks:

• 6/17/2026 – Humacyte had its price target lowered by TD Cowen from $1.50 to $1.25. They now have a “buy” rating on the stock.
• 6/16/2026 – Humacyte had its “buy” rating reaffirmed by BTIG Research. They now have a $2.00 price target on the stock.
• 6/11/2026 – Humacyte had its price target raised by HC Wainwright from $3.00 to $4.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Humacyte had its “buy” rating reaffirmed by BTIG Research. They now have a $2.00 price target on the stock.
• 6/1/2026 – Humacyte had its price target raised by Benchmark Co. to $2.00. They now have a “speculative buy” rating on the stock.
• 5/26/2026 – Humacyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock.
• 5/16/2026 – Humacyte was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/13/2026 – Humacyte had its price target lowered by BTIG Research from $3.00 to $2.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Humacyte had its “buy” rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
• 4/28/2026 – Humacyte had its “buy” rating reaffirmed by BTIG Research. They now have a $3.00 price target on the stock.

Insider Buying and Selling at Humacyte

In other news, CFO Dale A. Sander sold 45,887 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the sale, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at $240,491.70. The trade was a 14.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shamik J. Parikh sold 45,887 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares of the company’s stock, valued at $245,441.70. This trade represents a 14.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is currently owned by company insiders.

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.